William Chou

Will Chou is an accomplished executive with significant experience in the biopharmaceutical industry. Currently serving as Chief Executive Officer of Passage Bio since October 2022, Will previously held the same role at Aruvant from November 2019 to October 2022. Will's tenure at Novartis spanned over a decade, where roles included Vice President, Global Commercial Disease Leader overseeing the launch of Kymriah, and Global Program Head for CTL019 in lymphoma. Notable responsibilities also involved developing commercialization models for CAR T therapies and managing cardiovascular marketing strategies. Earlier in Will's career, project leadership was demonstrated at the Boston Consulting Group. Will holds an MBA from the Yale School of Management and an MD from the University of Pittsburgh School of Medicine.